🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being described as a "huge turning point" in the fight against superbug strains of the infection, according to scientists.

An International Challenge

Gonorrhoea infections are increasing globally, with data suggesting more than 82 million new cases per year. Particularly high rates are seen in Africa and countries within the WHO's designated area, which encompasses Mongolia and China to New Zealand. In England, cases have reached a record high, while figures across Europe in 2023 were triple the level compared to the rates from 2014.

“The authorization of novel therapies for gonorrhoea is an critical and opportune development in the reality of increasing worldwide cases, the spread of superbugs and the extremely scarce treatment choices presently on offer.”

Medical experts are particularly alarmed about the rise in treatment-resistant strains. The WHO has designated it as a "priority pathogen". Recent surveillance revealed that resistance to standard treatments like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

A Pair of Novel Treatment Options Gain Authorization

Zoliflodacin, also known as a brand name, was authorized by the US Food and Drug Administration in mid-December for treating gonorrhoea. This disease can lead to significant complications, including the inability to conceive. Scientists hope that specific application of this new drug will help hinder the spread of drug resistance.

Gepotidacin, developed by the drugmaker GSK, gained clearance in concurrent days. This medication, which is also used to treat urinary tract infections, was demonstrated in studies to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Approach to Creation

This new treatment stemmed from a new, not-for-profit approach for drug creation. The charitable organization GARDP partnered with the pharmaceutical company its industry partner to bring it to fruition.

“This approval signifies a huge turning point in the therapy of superbug gonorrhoea, which previously has been staying ahead of antibiotic development.”

Clinical Trial Data and Global Access

Based on findings released by a prominent scientific publication, zoliflodacin cured over nine in ten of genital gonorrhoea infections. This places it at an similar efficacy with the typical regimen, which combines an injection and a pill. The study enrolled nearly 1,000 volunteers from multiple nations including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its collaboration, GARDP has the rights to make available and distribute the drug in many developing nations.

Doctors directly involved have expressed optimism. The availability of a one-pill regimen of this kind is hailed as a "game-changer" for public health efforts. This is considered vital to reduce the burden of the infection for people and to stop the proliferation of highly drug-resistant gonorrhoea globally.